### Table summarizing the codes available in this repository for the respective analysis/figures/tables
  
| Analysis/Figures/Tables                 | Section in the manuscript    | Name of the Github folder |	
| :------------------------: |:-------------:| :-------------: |
| Fig 1A |	Study cohort and proteogenomic profiling| Cohort_OmicsData_Overview |
| Data Pre-processing | STAR Method | Preprocessing |
| FFPE-Frozen data alignment| STAR Method | Preprocessing |
| Fig S1A-B | STAR Method | Preprocessing |
| Fig S1C | STAR Method | Preprocessing |
| Fig S1E-G | STAR Method | Preprocessing |
| Fig 1B	| Genomic alterations and their association with chemo-refractoriness| Response-Associatoin-Mut-LOH |
| Fig 1C	| Genomic alterations and their association with chemo-refractoriness| Response-Associatoin-Mut-LOH |
| Fig S1H	| Genomic alterations and their association with chemo-refractoriness| Response-Associatoin-Mut-LOH |
| Fig 1D	| Genomic alterations and their association with chemo-refractoriness| Response-Associatoin-Mut-LOH |
| Fig 1E | Transcripts, proteins, and CNVs associated with chemo-refractoriness | Response-Associatoin-CNV-RNA-protein |
| Fig 1F | Integrative analysis (CNV, RNA, protein) identifies chemotherapy response-associated genes | Response-Associatoin-CNV-RNA-protein |
| Fig 1G | Integrative analysis (CNV, RNA, protein) identifies chemotherapy response-associated genes | Response-Associatoin-CNV-RNA-protein |
| Fig S1I | Integrative analysis (CNV, RNA, protein) identifies chemotherapy response-associated genes | Response-Associatoin-CNV-RNA-protein |
| Fig 2A | Cis regulation between CNV, RNA, and protein differs between sensitive and refractory tumors | Cis-regulation |
| Fig 2B | Cis regulation between CNV, RNA, and protein differs between sensitive and refractory tumors | Cis-regulation |
| Fig S2A | Cis regulation between CNV, RNA, and protein differs between sensitive and refractory tumors | Cis-regulation |
| Fig S2B | Chromosome 17 loss-of-heterozygosity (Chr17-LOH) is associated with chemo-sensitivity | Chr17LOH |
| Fig 2C-D | Chromosome 17 loss-of-heterozygosity (Chr17-LOH) is associated with chemo-sensitivity | Chr17LOH |
| Fig 2E | Chromosome 17 loss-of-heterozygosity (Chr17-LOH) is associated with chemo-sensitivity | Chr17LOH |
| Fig 2F | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig S2C-D | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig 2G | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig 2H | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig S2E-G | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig 2I | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig S2H | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig S2I | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig 2J | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig S2J | Bi-allelic and functional TP53 inactivation is associated with chemo-sensitivity | TP53 |
| Fig 2K-N | Proteins associated with chemotherapy response in tumors stratified by Chr17-LOH, BRCA1/2, and TP53 mutations | Trans-regulation |

















